1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Pfizer Fires Shot Across RSV Bow With Topline Data In Younger Adults

 
• By Alaric DeArment

The drug maker previously said approval in adults 18-59 could drive some evolution in a space where 60 mostly remains the lower limit for recommended use of RSV vaccines.

• Source: Shutterstock

Competition in the space of respiratory syncytial virus (RSV) vaccines has gotten a little hotter as Pfizer Inc.’s Abrysvo has beaten rival GSK plc’s Arexvy to the punch with topline results showing efficacy in patients aged 18-59 as well as 60 and older with immunocompromising conditions that place them at increased risk of severe RSV infection.

New York-based Pfizer announced 12 August topline and immunogenicity results from substudy B of the Phase III MONeT trial evaluating two doses of Abrysvo in immunocompromised adults aged 18 and older who are at risk of developing RSV-associated lower respiratory tract disease (RSV-LRTD)

Key Takeaways

  • Pfizer announced topline data showing Abrysvo is effective in preventing RSV-LRTD in immunocompromised adults aged 18-59.

  • The company plans to submit the data to regulators, and rival GSK expects to unveil data in a similar age group later in the year

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

In Brief: Genmab To Seek FDA Nod For Epkinly In Lymphoma

 
• By Sushmita Panda

Genmab will submit an sBLA for Epkinly in R/R follicular lymphoma in H1 2025, backed by positive Phase III data.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

More from R&D

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.